| January 1, 2028 |
JNJ |
Nipocalimab in Moderate to Severe Sjogren's Disease |
Trial Milestone |
Phase 3 |
| January 1, 2028 |
JAZZ |
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer |
Trial Milestone |
Phase 2 |
| January 5, 2028 |
PFE |
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| January 5, 2028 |
ALNY |
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) |
Trial Milestone |
Phase 1/Phase 2 |
| January 7, 2028 |
REGN |
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma |
Trial Milestone |
Phase 3 |
| January 8, 2028 |
MRK |
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). |
Trial Milestone |
Phase 2 |
| January 15, 2028 |
ABBV |
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies |
Trial Milestone |
Phase 2 |
| January 15, 2028 |
GILD |
Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed |
Trial Milestone |
Phase 2/Phase 3 |
| January 15, 2028 |
ARGX |
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome |
Trial Milestone |
Phase 2 |
| January 15, 2028 |
BNTX |
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma |
Trial Milestone |
Phase 2 |
| January 15, 2028 |
IBRX |
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer |
Trial Milestone |
Phase 1 |
| January 15, 2028 |
XENE |
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) |
Trial Milestone |
Phase 3 |
| January 15, 2028 |
KPTI |
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. |
Trial Milestone |
Phase 2 |
| January 15, 2028 |
ACAD |
ACP-204 in Adults With Alzheimer's Disease Psychosis |
Trial Milestone |
Phase 2/Phase 3 |
| January 15, 2028 |
MDGL |
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis |
Trial Milestone |
Phase 3 |
| January 15, 2028 |
SUPN |
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD |
Trial Milestone |
Phase 4 |
| January 15, 2028 |
NRIX |
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) |
Trial Milestone |
Phase 2 |
| January 15, 2028 |
MBX |
A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism |
Trial Milestone |
Phase 3 |
| January 15, 2028 |
IMTX |
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma |
Trial Milestone |
Phase 3 |
| January 15, 2028 |
TYRA |
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations |
Trial Milestone |
Phase 1 |
| January 15, 2028 |
CRMD |
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) |
Trial Milestone |
Phase 3 |
| January 15, 2028 |
FATE |
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| January 17, 2028 |
AGIO |
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria |
Trial Milestone |
Phase 1 |
| January 19, 2028 |
JNJ |
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring |
Trial Milestone |
Phase 1 |
| January 19, 2028 |
NVO |
A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity |
Trial Milestone |
Phase 1 |
| January 21, 2028 |
REGN |
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes |
Trial Milestone |
Phase 2 |
| January 25, 2028 |
MRK |
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) |
Trial Milestone |
Phase 3 |
| January 26, 2028 |
REGN |
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) |
Trial Milestone |
Phase 2 |
| January 28, 2028 |
REGN |
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea |
Trial Milestone |
Phase 2 |
| January 28, 2028 |
JAZZ |
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma |
Trial Milestone |
Phase 1/Phase 2 |
| January 29, 2028 |
AMGN |
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease |
Trial Milestone |
Phase 2 |
| January 30, 2028 |
VRTX |
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) |
Trial Milestone |
Phase 3 |
| January 31, 2028 |
BIIB |
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old |
Trial Milestone |
Phase 2 |
| January 31, 2028 |
JAZZ |
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC |
Trial Milestone |
Phase 2 |
| January 31, 2028 |
CATX |
Lead-212 PSV359 Therapy for Patients With Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |